Cited by 355Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 226 of the 228 references it cites were found in a registry or an index.

HDL-targeted therapies: progress, failures and future

Kingwell, Bronwyn A., Chapman, M. John, Kontush, Anatol, Miller, Norman E.·2014·Nature Reviews Drug Discovery

Open this paper in CoChat — free account

Abstract

Since the discovery in the 1970s that plasma levels of high-density lipoprotein cholesterol (HDL-C) are inversely associated with cardiovascular outcome, it has been postulated that HDL is anti-atherogenic and that increasing HDL-C levels is a promising therapeutic strategy. However, the recent failure of three orally active, HDL-C-raising agents has introduced considerable controversy, prompting the question of whether increasing the cholesterol cargo of HDL in a non-selective manner is an effective pharmacological approach for the translation of its atheroprotective and vasculoprotective activities. The interrelationships between HDL-C concentration, HDL particle number and levels of diverse HDL particle subpopulations of defined composition are complex, as are their relationships with reverse cholesterol transport and other anti-atherogenic functions. Such complexity highlights the incompleteness of our understanding of the biology of HDL particles. This article examines the HDL hypothesis in molecular and mechanistic terms, focusing on features that have been addressed, those that remain to be tested, and potential new targets for future pharmacological interventions.

Integrity signals

Registry

Crossref · 10.1038/nrd4279

Cites

226 of 226 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citation
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
Self-citation
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study
Castelli, W. P., Doyle, J. T., Gordon, T., Hames, C. G., Hjortland, M. C., Hulley, S. B., Kagan, A., & Zukel, W. J. (1977) · Circulation · doi:10.1161/01.cir.55.5.767 · Cited by 1,492
Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host
Khovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., & Grunfeld, C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r300019-jlr200 · Cited by 1,481
Molecular physiology of reverse cholesterol transport.
Fielding, C. J., & Fielding, P. E. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39898-9 · Cited by 1,448
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study
(2000) · Circulation · doi:10.1161/01.cir.102.1.21 · Cited by 1,273
MiR-33 Contributes to the Regulation of Cholesterol Homeostasis
Rayner, K. J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M. L., Tamehiro, N., Fisher, E. A., Moore, K. J., & Fernández-Hernando, C. (2010) · Science · doi:10.1126/science.1189862 · Cited by 1,260
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citation
Mendelian randomization: prospects, potentials, and limitations
Smith, G. D. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh132 · Cited by 1,222
THE TROMSØHEART-STUDY
Miller, N. E., Thelle, D. S., Førde, O. H., & Mjøs, O. D. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92274-7 · Cited by 1,206
Self-citation
New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport
Lewis, G. F., & Rader, D. J. (2005) · Circulation Research · doi:10.1161/01.res.0000170946.56981.5c · Cited by 1,104
Update on acute coronary syndromes: the pathologists' view
Falk, E., Nakano, M., Bentzon, J. F., Finn, A. V., & Virmani, R. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs411 · Cited by 1,047
MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis
Najafi-Shoushtari, S. H., Kristo, F., Li, Y., Shioda, T., Cohen, D. E., Gerszten, R. E., & Näär, A. M. (2010) · Science · doi:10.1126/science.1189123 · Cited by 957
Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport
Rosenson, R. S., Brewer, H. B., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.-C., Phillips, M. C., Rader, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.066589 · Cited by 953
Plasma cholesteryl ester transfer protein
Tall, A. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36957-1 · Cited by 953
Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions
Sharrett, A. R., Ballantyne, C. M., Coady, S., HEISS, G. M., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 942
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Stability and Instability: Two Faces of Coronary Atherosclerosis
Davies, M. J. (1996) · Circulation · doi:10.1161/01.cir.94.8.2013 · Cited by 923
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
Robins, S. J., Collins, D. E., Wittes, J. T., Papademetriou, V., DEEDWANIA, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., WEXLER, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 917
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study
McQueen, M. J., Hawken, S., Wang, X., Ounpuu, S., Sniderman, A., Probstfield, J., Steyn, K., Sanderson, J. E., Hasani, M., Volkova, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61076-4 · Cited by 864
Increased High-Density Lipoprotein Levels Caused by a Common Cholesteryl-Ester Transfer Protein Gene Mutation
Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 862
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.
Lenten, B. J. V., Hama, S. Y., de Beer, F. C., Stafforini, D. M., McIntyre, T. M., Prescott, S. M., Du, B. N. L., Fogelman, A. M., & Navab, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118345 · Cited by 839
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Mendelian randomization of blood lipids for coronary heart disease
Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P., Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/eht571 · Cited by 748
Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis A Randomized Controlled Trial
Tardif, J. (2007) · JAMA · doi:10.1001/jama.297.15.jpc70004 · Cited by 725
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
Rayner, K. J., Esau, C. C., Hussain, F. N., McDaniel, A. L., Marshall, S. M., van Gils, J. M., Ray, T. D., Sheedy, F. J., Goedeke, L., Liu, X., et al. (2011) · Nature · doi:10.1038/nature10486 · Cited by 706
High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport
Assmann, G., Schulte, H., von Eckardstein, A., & Huang, Y. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05852-2 · Cited by 700
Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation
Varbo, A., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Circulation · doi:10.1161/circulationaha.113.003008 · Cited by 692
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis
Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Kontush, A., & Chapman, M. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.1 · Cited by 647
Self-citation
Early incorporation of cell-derived cholesterol into pre-.beta.-migrating high-density lipoprotein
Castro, G. R., & Fielding, C. J. (1988) · Biochemistry · doi:10.1021/bi00401a005 · Cited by 641
Protein-lipid relationships in human plasma
Barr, D. P., Russ, E. M., & Eder, H. A. (1951) · The American Journal of Medicine · doi:10.1016/0002-9343(51)90183-0 · Cited by 635
Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.
Zhong, S., Sharp, D. S., Grove, J., Bruce, C., Yano, K., Curb, J. D., & Tall, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118751 · Cited by 579
Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Gotto, A. M., Whitney, E. J., Stein, E. A., Shapiro, D. R., Clearfield, M. B., Weis, S. E., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 558
Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial
Otvos, J. D., Collins, D. E., Freedman, D. S., SHALAUROVA, I. Y., Schaefer, E. J., McNamara, J. R., Bloomfield, H. E., & Robins, S. J. (2006) · Circulation · doi:10.1161/circulationaha.105.565135 · Cited by 542
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease
Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42946 · Cited by 535
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K., & Shinkai, H. (2000) · Nature · doi:10.1038/35018119 · Cited by 532
HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events
Rosenson, R. S., Brewer, H. B., Chapman, M. J., Fazio, S., Hussain, M. M., Kontush, A., Krauss, R. M., Otvos, J. D., Remaley, A. T., & Schaefer, E. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155333 · Cited by 523
Self-citation
Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
The Tromsø Heart Study
Thelle, D. S., Arnesen, E., & Førde, O. H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198306163082405 · Cited by 493
Biological activities of HDL subpopulations and their relevance to cardiovascular disease
Camont, L., Chapman, M. J., & Kontush, A. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.013 · Cited by 484
Self-citation
Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis
Martinez, L. O., Jacquet, S., Estève, J., Rolland, C., Cabezón, E., Champagne, É., Pineau, T., Georgeaud, V., Walker, J. E., Tercé, F., et al. (2003) · Nature · doi:10.1038/nature01250 · Cited by 459
Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein
Marotti, K. R., Castle, C. K., Boyle, T. P., Lin, A. H., Murray, R. W., & Melchior, G. W. (1993) · Nature · doi:10.1038/364073a0 · Cited by 444
High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus
Drew, B. G., Duffy, S. J., Formosa, M. F., Natoli, A. K., Henstridge, D. C., Penfold, S. A., Thomas, W. G., Mukhamedova, N., de Courten, B., Forbes, J. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.843219 · Cited by 443
Self-citation
High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men
Spieker, L. E., Sudano, I., Hürlimann, D., Lerch, P. G., Lang, M. G., Binggeli, C., Corti, R., Ruschitzka, F. T., Lüscher, T. F., & Noll, G. (2002) · Circulation · doi:10.1161/01.cir.0000013424.28206.8f · Cited by 437
Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function
Davidson, W. S., Silva, R. A. G. D., Chantepie, S., Lagor, W. R., Chapman, M. J., & Kontush, A. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.186031 · Cited by 415
Self-citation
ATP-Binding Cassette Cholesterol Transporters and Cardiovascular Disease
Oram, J. F., & Vaughan, A. M. (2006) · Circulation Research · doi:10.1161/01.res.0000250171.54048.5c · Cited by 411
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol: A Randomized Controlled Trial
Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410
Unraveling the complexities of the HDL lipidome
Kontush, A., Lhomme, M., & Chapman, M. J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036095 · Cited by 409
Self-citation
Association of Cholesteryl Ester Transfer Protein– Taq IB Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk
Ordovás, J. M., Cupples, L. A., Corella, D., Otvos, J. D., Osgood, D. P., Martinez, A. A., Lahoz, C., Coltell, Ó., Wilson, P. W. F., & Schaefer, E. J. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.5.1323 · Cited by 379
Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events
Mackey, R. H., Greenland, P., Goff, D. C., Lloyd‐Jones, D. M., Sibley, C. T., & Mora, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.060 · Cited by 371
An abundant dysfunctional apolipoprotein A1 in human atheroma
Huang, Y. R., DiDonato, J. A., Levison, B. S., Schmitt, D., Li, L., Wu, Y., Buffa, J. A., Kim, T., Gerstenecker, G. S., Gu, X., et al. (2014) · Nature Medicine · doi:10.1038/nm.3459 · Cited by 369
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study
Manninen, V., Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Op, H., & Frick, H. M. (1992) · Circulation · Cited by 360
Antiatherogenic small, dense HDL—guardian angel of the arterial wall?
Kontush, A., & Chapman, M. J. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0500 · Cited by 355
Self-citation
Protein-lipid relationships in human plasma
Russ, E. M., Eder, H. A., & Barr, D. P. (1951) · The American Journal of Medicine · doi:10.1016/0002-9343(51)90182-9 · Cited by 351
The metabolism and anti-atherogenic properties of HDL
Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., & Barter, P. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800034-jlr200 · Cited by 331
Characterization of Levels and Cellular Transfer of Circulating Lipoprotein-Bound MicroRNAs
Wagner, J., Riwanto, M., Besler, C., Knau, A., Fichtlscherer, S., Roexe, T., Zeiher, A. M., Landmesser, U., & Dimmeler, S. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300741 · Cited by 330
Small, Dense High-Density Lipoprotein-3 Particles Are Enriched in Negatively Charged Phospholipids
Camont, L., Lhomme, M., Rached, F. H., Goff, W. L., Nègre‐Salvayre, A., Salvayre, R., Calzada, C., Lagarde, M., Chapman, M. J., & Kontush, A. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301468 · Cited by 330
Self-citation
HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells
Feig, J. E., Rong, J. X., Shamir, R., Sanson, M., Vengrenyuk, Y., Liu, J., Rayner, K. J., Moore, K. J., Garabedian, M. J., & Fisher, E. A. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016086108 · Cited by 313
The emerging role of HDL in glucose metabolism
Drew, B. G., Rye, K.-A., Duffy, S. J., Barter, P., & Kingwell, B. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.235 · Cited by 307
Self-citation
A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients
McKenney, J. M. (1994) · JAMA · doi:10.1001/jama.1994.03510330050033 · Cited by 303
HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway
Matsuura, F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27602 · Cited by 296
Acute Coronary Events
Arbab‐Zadeh, A., Nakano, M., Virmani, R., & Fuster, V. (2012) · Circulation · doi:10.1161/circulationaha.111.047431 · Cited by 292
Effects of High-Density Lipoproteins on Pancreatic β-Cell Insulin Secretion
Fryirs, M. A., Barter, P. J., Appavoo, M., Tuch, B. E., Tabet, F., Heather, A. K., & Rye, K. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.207373 · Cited by 288
Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects With Isolated Low High-Density Lipoprotein
Bisoendial, R. J., Hovingh, G. K., Levels, J. H. M., Lerch, P. G., Andresen, I., Hayden, M. R., Kastelein, J. J. P., & Stroes, E. S. G. (2003) · Circulation · doi:10.1161/01.cir.0000070934.69310.1a · Cited by 287
Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy
Kini, A. S., Baber, U., Kovacic, J. C., Limaye, A. M., Ali, Z. A., Sweeny, J. M., Maehara, A., Mehran, R., Dangas, G., Mintz, G. S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.058 · Cited by 283
Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque
Shaw, J. A., Bobik, A., Murphy, A. J., Kanellakis, P., Blombery, P. A., Mukhamedova, N., Woollard, K. J., Lyon, S. M., Sviridov, D., & Dart, A. M. (2008) · Circulation Research · doi:10.1161/circresaha.108.182063 · Cited by 280
Is it time to revise the HDL cholesterol hypothesis?
Rader, D. J., & Tall, A. R. (2012) · Nature Medicine · doi:10.1038/nm.2937 · Cited by 279
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
Bruckert, E., Labreuche, J., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.023 · Cited by 273
Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene.
Hayek, T., Masucci-Magoulas, L., Jiang, X. L., Walsh, A., Rubin, E. M., Breslow, J. L., & Tall, A. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118255 · Cited by 265
Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
Barter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p002816 · Cited by 259
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*
Chapman, M. J., Assmann, G., Fruchart, J., Shepherd, J., & Sirtori, C. R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004402 · Cited by 257
Self-citation
Apolipoprotein A-I Mimetic Peptides
Navab, M., Anantharamaiah, G. M., Reddy, S. T., Hama, S. Y., Hough, G., Grijalva, V. R., Yu, N., Ansell, B. J., Datta, G., Garber, D. W., et al. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000165694.39518.95 · Cited by 246
Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
Yvan‐Charvet, L., Kling, J., Pagler, T. A., Li, H., Hubbard, B. K., Fisher, T., Sparrow, C. P., Taggart, A. K. P., & Tall, A. R. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.207142 · Cited by 242
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
Bloomfield, D. M., Carlson, G. L., Sapre, A., Tribble, D. L., McKenney, J. M., Littlejohn, T. W., Sisk, C. M., Mitchel, Y., & Pasternak, R. C. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.09.022 · Cited by 242
High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy
Mora, S., Glynn, R. J., & Ridker, P. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002671 · Cited by 241
RVX-208
Bailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G. S., Hansen, H. C., Chiacchia, F. S., Johansson, J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.035 · Cited by 239
Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice
Westerterp, M., van der Hoogt, C. C., de Haan, W., Offerman, E. H., Dallinga‐Thie, G. M., Jukema, J. W., Havekes, L. M., & Rensen, P. C. N. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000243925.65265.3c · Cited by 231
Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study
Contois, J. H., McNamara, J. R., Lammi‐Keefe, C. J., Wilson, P. W. F., Massov, T., & Schaefer, E. J. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.4.515 · Cited by 231
Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion
Brousseau, M. E., Diffenderfer, M. R., Millar, J. S., Nartsupha, C., Asztalos, B. F., Welty, F. K., Wolfe, M. L., Rudling, M. J., Björkhem, I., Angelin, B., et al. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000161928.16334.dd · Cited by 230
Preferential Sphingosine-1-Phosphate Enrichment and Sphingomyelin Depletion Are Key Features of Small Dense HDL3 Particles
Kontush, A., Thérond, P., Zerrad-Saadi, A., Couturier, M., Nègre‐Salvayre, A., Souza, J. A., Chantepie, S., & Chapman, M. J. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.145672 · Cited by 228
Self-citation
Translation of High-Density Lipoprotein Function Into Clinical Practice
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P. J., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2013) · Circulation · doi:10.1161/circulationaha.113.000962 · Cited by 225
Self-citation
Cholesteryl Ester Transfer Protein Corrects Dysfunctional High Density Lipoproteins and Reduces Aortic Atherosclerosis in Lecithin Cholesterol Acyltransferase Transgenic Mice
Föger, B., Chase, M. B., Amar, M. J., Vaisman, B. L., Shamburek, R. D., Paigen, B. J., Fruchart‐Najib, J., Paiz, J. A., Koch, C. A., Hoyt, R. F., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.36912 · Cited by 224
A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome
Waksman, R., Torguson, R., Kent, K. M., Pichard, A. D., Suddath, W. O., Satler, L. F., Martin, B. D., Perlman, T. J., Maltais, J. B., Weissman, N. J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.067 · Cited by 224
Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study‡
Assmann, G., Schulte, H., Cullen, P., & Seedorf, U. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01888.x · Cited by 220
MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice
Horie, T., Baba, O., Kuwabara, Y., Chujo, Y., Watanabe, S., Kinoshita, M., Horiguchi, M., Nakamura, T., Chonabayashi, K., Hishizawa, M., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003376 · Cited by 220
Implications for Treatment
Lindvall, C., & Lask, B. D. (2011) · Wiley eBooks · doi:10.1002/9781119998402.ch10 · Cited by 219
Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women
Boekholdt, S. M., Kuivenhoven, J. A., Wareham, N. J., Peters, R. J. G., Jukema, J. W., Luben, R., Bingham, S. A., Day, N., Kastelein, J. J. P., & Khaw, K. (2004) · Circulation · doi:10.1161/01.cir.0000141730.65972.95 · Cited by 217
Consumption of Saturated Fat Impairs the Anti-Inflammatory Properties of High-Density Lipoproteins and Endothelial Function
Nicholls, S. J., Lundman, P., Harmer, J. A., Cutri, B., Griffiths, K. A., Rye, K.-A., Barter, P. J., & Celermajer, D. S. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.080 · Cited by 216
Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study
Parish, S., Offer, A. R., Clarke, R., Hopewell, J. C., Hill, M., Otvos, J. D., Armitage, J., & Collins, R. (2012) · Circulation · doi:10.1161/circulationaha.111.073684 · Cited by 212
Impact of Statin Therapy on Plaque Characteristics as Assessed by Serial OCT, Grayscale and Integrated Backscatter–IVUS
Hattori, K., Ozaki, Y., Ismail, T. F., Okumura, M., Naruse, H., Kan, S. C., Ishikawa, M., Kawai, T., Ohta, M., Kawai, H., et al. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2011.11.012 · Cited by 211
High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithinchoesteryl acyltransferase
Bérard, A. M., Föger, B., Remaley, A. T., Shamburek, R. D., Vaisman, B. L., Talley, G. D., Paigen, B. J., Hoyt, R. F., Marcovina, S. M., Brewer, H. B., et al. (1997) · Nature Medicine · doi:10.1038/nm0797-744 · Cited by 209
Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes
Silva, R. A. G. D., Huang, R., Morris, J. C., Fang, J., Gracheva, E. O., Ren, G., Kontush, A., Jerome, W. G., Rye, K., & Davidson, W. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803626105 · Cited by 206
Self-citation
Reconstituted High-Density Lipoprotein Increases Plasma High-Density Lipoprotein Anti-Inflammatory Properties and Cholesterol Efflux Capacity in Patients With Type 2 Diabetes
Patel, S., Drew, B. G., Nakhla, S., Duffy, S. J., Murphy, A. J., Barter, P. J., Rye, K., Chin-Dusting, J. P. F., Hoang, A., Sviridov, D., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.008 · Cited by 203
Self-citation
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Murphy, A. J., Bijl, N., Yvan‐Charvet, L., Welch, C. L., Bhagwat, N., Adili, R., Wang, Y., Shaw, J. A., Levine, R. L., Ni, H., et al. (2013) · Nature Medicine · doi:10.1038/nm.3150 · Cited by 201
Serum Amyloid A in Uremic HDL Promotes Inflammation
Weichhart, T., Kopecky, C., Kubicek, M., Haidinger, M., Döller, D., Katholnig, K., Suarna, C., Eller, P., Tölle, M., Gerner, C., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011070668 · Cited by 201
Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Calkin, A. C., Drew, B. G., Ono, A., Duffy, S. J., Gordon, M. V., Schoenwaelder, S. M., Sviridov, D., Cooper, M. E., Kingwell, B. A., & Jackson, S. P. (2009) · Circulation · doi:10.1161/circulationaha.109.870709 · Cited by 198
Self-citation
Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial
Barter, P. J., Rye, K., Tardif, J., Waters, D. D., Boekholdt, S. M., Breazna, A., & Kastelein, J. J. P. (2011) · Circulation · doi:10.1161/circulationaha.111.018259 · Cited by 198
Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux.
Banka, C. L., Yuan, T., de Beer, M. C., Kindy, M. S., Curtiss, L. K., & de Beer, F. C. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39863-1 · Cited by 197
The Current State of Niacin in Cardiovascular Disease Prevention
Lavigne, P. M., & Karas, R. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.030 · Cited by 185
Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?
Kunnen, S., & Eck, M. V. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024513 · Cited by 181
Atherosclerotic Disease in Marked Hyperalphalipoproteinemia
Hirano, K., Yamashita, S., Kuga, Y., Sakai, N., Nozaki, S., Kihara, S., Arai, T., Yanagi, K., Takami, S., Menju, M., et al. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.11.1849 · Cited by 175
Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease
Nicholls, S. J., Gordon, A., Johansson, J., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Taylor, A. J., Borgman, M., & Nissen, S. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.015 · Cited by 172
High-Density Lipoprotein and Atherosclerosis Regression
Feig, J. E., Hewing, B., Smith, J. D., Hazen, S. L., & Fisher, E. A. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.300760 · Cited by 172
Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice
Mertens, A. C., Verhamme, P. B., Bielicki, J. K., Phillips, M. C., Quarck, R. A., Verreth, W., Stengel, D., Ninio, E., Navab, M., Mackness, B., et al. (2003) · Circulation · doi:10.1161/01.cir.0000056523.08033.9f · Cited by 171
Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?
Barter, P. J., & Rye, K. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.148817 · Cited by 151
Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL
Clay, M. A., Newnham, H. H., Forte, T. M., & Barter, P. J. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90125-f · Cited by 150
Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins
Lamon‐Fava, S., Diffenderfer, M. R., Barrett, P. H. R., Buchsbaum, A., Nyaku, M. K., Horvath, K. V., Asztalos, B. F., Otokozawa, S., Ai, M., Matthan, N. R., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.164541 · Cited by 150
Expression of Cholesteryl Ester Transfer Protein in Mice Promotes Macrophage Reverse Cholesterol Transport
Tanigawa, H., Billheimer, J. T., Tohyama, J., Zhang, Y., Rothblat, G. H., & Rader, D. J. (2007) · Circulation · doi:10.1161/circulationaha.107.704254 · Cited by 149
Relationship Between Atheroma Regression and Change in Lumen Size After Infusion of Apolipoprotein A-I Milano
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Schoenhagen, P., Crowe, T., Kapadia, S., & Nissen, S. E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.040 · Cited by 147
Intravenous apoA-I/lecithin discs increase pre-β-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans
Nanjee, M. N., Cooke, C. J., Garvin, R. A., Semeria, F. J., Lewis, G. F., Olszewski, W. L., & Miller, N. E. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32212-4 · Cited by 144
Self-citation
Acute Effects of Intravenous Infusion of ApoA1/Phosphatidylcholine Discs on Plasma Lipoproteins in Humans
Nanjee, M. N., Doran, J. E., Lerch, P. G., & Miller, N. E. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.4.979 · Cited by 143
Self-citation
Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes
Marso, S. P., Mercado, N. F., Maehara, A., Weisz, G., Mintz, G. S., McPherson, J., Schiele, F., Dudek, D., Fahy, M. P., Xu, K., et al. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2012.01.008 · Cited by 142
Liver X receptors (LXR) as therapeutic targets in dyslipidemia
Bełtowski, J. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2008.00062.x · Cited by 132
Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins.
Liang, H.-Q., Rye, K., & Barter, P. J. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39962-4 · Cited by 131
Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux
Diditchenko, S., Gille, A., Pragst, I., Stadler, D., Waelchli, M., Hamilton, R., Leis, A. P., & Wright, S. D. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301981 · Cited by 129
Large and Cholesteryl Ester-Rich High-Density Lipoproteins in Cholesteryl Ester Transfer Protein (CETP) Deficiency Can Not Protect Macrophages from Cholesterol Accumulation Induced by Acetylated Low-Density Lipoproteins1
Ishigami, M., Yamashita, S., Sakai, N., Aral, T., Hirano, K., Hiraoka, H., Kameda-Takemura, K., & Matsuzawa, Y. (1994) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a124516 · Cited by 128
Regulation of High-Density Lipoprotein Metabolism
Rye, K., & Barter, P. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.300632 · Cited by 128
Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community
Vasan, R. S., Pencina, M. J., Robins, S. J., Zachariah, J. P. V., Jasuja, G. K., D’Agostino, R. B., & Ordovás, J. M. (2009) · Circulation · doi:10.1161/circulationaha.109.872705 · Cited by 128
Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A‐I
Souza, J. A., Vindis, C., Nègre‐Salvayre, A., Rye, K., Couturier, M., Thérond, P., Chantepie, S., Salvayre, R., Chapman, M. J., & Kontush, A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00713.x · Cited by 128
Self-citation
The Tromsø Heart Study: Serum apolipoprotein Al concentration in relation to future coronary heart disease
ISHIKAWA, T., Fidge, N., Thelle, D. S., Førde, O. H., & Miller, N. E. (1978) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1978.tb00832.x · Cited by 126
Self-citation
Mendelian Randomization in the Era of Genomewide Association Studies
Abou‐Sleiman, P. M., & Grant, S. F. A. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.141564 · Cited by 123
On the mechanism for PPAR agonists to enhance ABCA1 gene expression
Ogata, M., Tsujita, M., Hossain, M. A., Akita, N., Gonzalez, F. J., Staels, B., Suzuki, S., Fukutomi, T., Kimura, G., & Yokoyama, S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.008 · Cited by 120
Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins
石神, 眞. (1996) · Medical Entomology and Zoology · doi:10.11501/3119662 · Cited by 120
Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100
Véniant, M. M., Sullivan, M. A., Kim, S. K., Ambroziak, P., Chu, A., Wilson, M. D., Hellerstein, M. K., Rudel, L. L., Walzem, R. L., & Young, S. G. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10695 · Cited by 114
Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia
Huang, Z., Inazu, A., Nohara, A., Higashikata, T., & Mabuchi, H. (2002) · Clinical Science · doi:10.1042/cs1030587 · Cited by 113
Cholesteryl Ester Transfer Protein and Mortality in Patients Undergoing Coronary Angiography: The Ludwigshafen Risk and Cardiovascular Health Study
Ritsch, A., Scharnagl, H., Eller, P., Tancevski, I., Duwensee, K., Demetz, E., Sandhofer, A., Boehm, B. O., Winkelmann, B. R., Patsch, J. R., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.875013 · Cited by 104
Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes.
Francone, O. L., Royer, L. J., & Haghpassand, M. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39156-2 · Cited by 104
Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: Plasma CETP regulates high-density lipoprotein concentration and composition
Yamashita, S., Hui, D. Y., Wetterau, J. R., Sprecher, D. L., Harmony, J. A. K., Sakai, N., Matsuzawa, Y., & Tarui, S. (1991) · Metabolism · doi:10.1016/0026-0495(91)90097-g · Cited by 102
Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice
Hambruch, E., Miyazaki‐Anzai, S., Hahn, U. K., Matysik, S., Boettcher, A., Perović‐Ottstadt, S., Schlüter, T., Kinzel, O. D., Krol, H. D., Deuschle, U., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.196519 · Cited by 100
Hepatic Lipase, Genetically Elevated High-Density Lipoprotein, and Risk of Ischemic Cardiovascular Disease
Johannsen, T. H., Kamstrup, P. R., Andersen, R. V., Jensen, G. B., Sillesen, H. H., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1342 · Cited by 99
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction
Regieli, J. J., Jukema, J. W., Grobbee, D. E., Kastelein, J. J. P., Kuivenhoven, J. A., Zwinderman, A. H., van der Graaf, Y., Bots, M. L., & Doevendans, P. A. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn465 · Cited by 99
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
Krauss, R. M., Wojnooski, K., Orr, J., Geaney, J. C., Pinto, C. A., Liu, Y., Wagner, J. A., Luk, J. A. M., Johnson‐Levonas, A. O., Anderson, M. S., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m018010 · Cited by 94
ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies
Nicholls, S. J., Gordon, A., Johannson, J., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Wong, N. C. W., Borgman, M., & Nissen, S. E. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6373-5 · Cited by 93
LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms
Verschuren, L., der Weij, J. D. V.-V., Zadelaar, S., Kleemann, R., & Kooistra, T. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800374-jlr200 · Cited by 93
FXR an emerging therapeutic target for the treatment of atherosclerosis
Mencarelli, A., & Fiorucci, S. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00997.x · Cited by 92
Lecithin:Cholesterol Acyltransferase Deficiency Increases Atherosclerosis in the Low Density Lipoprotein Receptor and Apolipoprotein E Knockout Mice
Furbee, J. W., Sawyer, J. K., & Parks, J. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109883200 · Cited by 91
High Pre-β1 HDL Concentrations and Low Lecithin: Cholesterol Acyltransferase Activities Are Strong Positive Risk Markers for Ischemic Heart Disease and Independent of HDL-Cholesterol
Sethi, A. A., Sampson, M., Warnick, R., Muniz, N., Vaisman, B., Nordestgaard, B. G., Tybjærg-Hansen, A., & Remaley, A. T. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.139931 · Cited by 91
MicroRNA Control of High-Density Lipoprotein Metabolism and Function
Rayner, K. J., & Moore, K. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.300645 · Cited by 91
HDL, Atherosclerosis, and Emerging Therapies
Hafiane, A., & Genest, J. J. (2013) · Cholesterol · doi:10.1155/2013/891403 · Cited by 82
High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides
Borggreve, S. E., Hillege, H. L., Dallinga‐Thie, G. M., de Jong, P. E., Wolffenbuttel, B. H. R., Grobbee, D. E., van Tol, A., Dullaart, R. P. F., & on behalf of the PREVEND Study Group (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm062 · Cited by 78
Effect of Recombinant Human Lecithin Cholesterol Acyltransferase Infusion on Lipoprotein Metabolism in Mice
Rousset, X., Vaisman, B. L., Auerbach, B. J., Krause, B. R., Homan, R., Stonik, J. A., Csákó, G., Shamburek, R. D., & Remaley, A. T. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169540 · Cited by 76
Composition and ultrastructure of size subclasses of normal human peripheral lymph lipoproteins: quantification of cholesterol uptake by HDL in tissue fluids
Nanjee, M. N., Cooke, C. J., Wong, J. S., Hamilton, R. L., Olszewski, W. L., & Miller, N. E. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31173-1 · Cited by 75
Self-citation
A new era for quantifying HDL and cardiovascular risk?
Heinecke, J. W. (2012) · Nature Medicine · doi:10.1038/nm.2930 · Cited by 74
Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study
Robins, S. J., Lyass, A., Brocia, R. W., Massaro, J. M., & Vasan, R. S. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.046 · Cited by 72
Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome
Kuller, L. H., Grandits, G. A., Cohen, J. D., Neaton, J. D., & Prineas, R. J. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.09.001 · Cited by 72
The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport
Tchoua, U., D’Souza, W., Mukhamedova, N., Blum, D., Niesor, E. J., Mizrahi, J. L., Maugeais, C., & Sviridov, D. (2007) · Cardiovascular Research · doi:10.1093/cvr/cvm087 · Cited by 72
Effect of Niacin Therapy on Cardiovascular Outcomes in Patients With Coronary Artery Disease
Duggal, J., Singh, M., Attri, N., Singh, P. P., Ahmed, N., Pahwa, S., Molnár, J., Singh, S., Khosla, S., & Arora, R. R. (2010) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248410361337 · Cited by 71
Effects of High-Density Lipoprotein Elevation With Cholesteryl Ester Transfer Protein Inhibition on Insulin Secretion
Siebel, A. L., Natoli, A. K., Yap, F. Y. T., Carey, A. L., Reddy-Luthmoodoo, M., Sviridov, D., Weber, C. I. K., Meneses‐Lorente, G., Maugeais, C., Forbes, J. M., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.300689 · Cited by 71
Self-citation
Relation of Increased Prebeta-1 High-Density Lipoprotein Levels to Risk of Coronary Heart Disease
Guey, L. T., Pullinger, C. R., Ishida, B. Y., O'Connor, P. M., Zellner, C., Francone, O. L., Laramie, J. M., Naya-Vigne, J. M., Siradze, K. A., Deedwania, P., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.054 · Cited by 70
ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden
Bochem, A. E., van Wijk, D. F., Holleboom, A. G., Duivenvoorden, R., Motazacker, M. M., Dallinga‐Thie, G. M., de Groot, E., Kastelein, J. J. P., Nederveen, A. J., Hovingh, G. K., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs376 · Cited by 70
Decreased High-Density Lipoprotein (HDL) Particle Size, Preβ-, and Large HDL Subspecies Concentration in Finnish Low-HDL Families
Watanabe, H., Söderlund, S., Soro‐Paavonen, A., Hiukka, A., Leinonen, E. S., Alagona, C., Salonen, R. M., Tuomainen, T., Ehnholm, C., Jauhiainen, M., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000209577.04246.c0 · Cited by 70
HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications
Remaley, A. T., Amar, M. J., & Sviridov, D. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.9.1203 · Cited by 69
High‐Density Lipoproteins
Kontush, A., & Chapman, M. J. (2011) · Wiley eBooks · doi:10.1002/9781118158678 · Cited by 68
Self-citation
Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus
Nieuwdorp, M., Vergeer, M., Bisoendial, R. J., Roodt, J. O. ’., Levels, H., Birjmohun, R. S., Kuivenhoven, J. A., Basser, R., Rabelink, T. J., Kastelein, J. J. P., et al. (2008) · Diabetologia · doi:10.1007/s00125-008-0975-2 · Cited by 67
Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein
Hoang, A., Drew, B. G., Low, H., Remaley, A. T., Nestel, P. J., Kingwell, B. A., & Sviridov, D. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr103 · Cited by 66
Self-citation
Apolipoprotein A-I-containing lipoproteins, with or without apolipoprotein A-II, as progenitors of pre-.beta. high-density lipoprotein particles
Hennessy, L. K., Kunitake, S. T., & Kane, J. P. (1993) · Biochemistry · doi:10.1021/bi00073a006 · Cited by 65
Future of High-Density Lipoprotein Infusion Therapies
Kingwell, B. A., & Chapman, M. J. (2013) · Circulation · doi:10.1161/circulationaha.113.002683 · Cited by 65
Self-citation
Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk
Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834477d2 · Cited by 64
Plasma levels of lecithin:cholesterol acyltransferase and risk offuture coronary artery disease in apparently healthy men and women: aprospective case-control analysis nested in the EPIC-Norfolk populationstudy
Holleboom, A. G., Kuivenhoven, J. A., Vergeer, M., Hovingh, G. K., van Miert, J. N. I., Wareham, N. J., Kastelein, J. J. P., Khaw, K., & Boekholdt, S. M. (2009) · Journal of Lipid Research · doi:10.1194/p900038-jlr200 · Cited by 64
Cholesteryl ester transfer protein: friend or foe?
Fielding, C. J., & Havel, R. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118719 · Cited by 63
Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin
Marschang, P., Sandhofer, A., Ritsch, A., Fiser, I., Kvas, E., & Patsch, J. R. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01674.x · Cited by 62
HUMAN CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION ENHANCES THE MOUSE SURVIVAL RATE IN AN EXPERIMENTAL SYSTEMIC INFLAMMATION MODEL
Cazita, P. M., Barbeiro, D. F., Moretti, A. I. S., Quintão, E. C. R., & Soriano, F. G. (2008) · Shock · doi:10.1097/shk.0b013e31816e30fd · Cited by 62
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study
Ballantyne, C. M., Miller, M. J., Niesor, E. J., Burgess, T., Kallend, D. G., & Stein, E. A. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.11.017 · Cited by 59
High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants
van Acker, B. A. C., Botma, G.-J., Zwinderman, A. H., Kuivenhoven, J. A., Dallinga‐Thie, G. M., Sijbrands, E. J. G., Boer, J. M. A., Seidell, J. C., Jukema, J. W., Kastelein, J. J. P., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.019 · Cited by 59
ABCA12 Regulates ABCA1-Dependent Cholesterol Efflux from Macrophages and the Development of Atherosclerosis
Fu, Y., Mukhamedova, N., Ip, S., D’Souza, W., Henley, K. J., DiTommaso, T., Kesani, R., Ditiatkovski, M., Jones, L. K., Lane, R. M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.07.003 · Cited by 55
Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors
Goodman, K. B., Bury, M. J., Cheung, M., Cichy-Knight, M. A., Dowdell, S. E., Dunn, A. K., Lee, D. M., Lieby, J. A., Moore, M. L., Scherzer, D. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.033 · Cited by 53
Prostaglandin D2-DP Signaling Promotes Endothelial Barrier Function via the cAMP/PKA/Tiam1/Rac1 Pathway
Kobayashi, K., Tsubosaka, Y., Hori, M., Narumiya, S., Ozaki, H., & Murata, T. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300993 · Cited by 53
Common Variation in the CETP Gene and the Implications for Cardiovascular Disease and its Treatment: An Updated Analysis
Dullaart, R. P. F., & Sluiter, W. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.6.747 · Cited by 52
Effects of Intravenous Apolipoprotein A-I/Phosphatidylcholine Discs on LCAT, PLTP, and CETP in Plasma and Peripheral Lymph in Humans
Kujiraoka, T., Nanjee, M. N., Oka, T., Ito, M., Nagano, M., Cooke, C. J., Takahashi, S., Olszewski, W. L., Wong, J. S., Stepanova, I. P., et al. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000089328.23279.3f · Cited by 49
Self-citation
Mendelian Disorders of High-Density Lipoprotein Metabolism
Oldoni, F., Sinke, R. J., & Kuivenhoven, J. A. (2014) · Circulation Research · doi:10.1161/circresaha.113.300634 · Cited by 49
Up‐regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA‐IMilano
Cimmino, G., Ibáñez, B., Vilahur, G., Speidl, W. S., Fuster, V., Badimón, L., & Badimón, J. J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00614.x · Cited by 48
Mice overexpressing human lecithin: cholesterol acvltransferase are not protected against diet‐induced atherosclerosis
Mehlum, A., MURI, M., Hagve, T., Solberg, L. A., & Prydz, H. (1997) · Apmis · doi:10.1111/j.1699-0463.1997.tb05095.x · Cited by 47
Metabolism of ApoA-I as Lipid-Free Protein or as Component of Discoidal and Spherical Reconstituted HDLs
Kee, P. H., Rye, K., Taylor, J. L., Barrett, P. H. R., & Barter, P. J. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000038485.94020.7f · Cited by 46
Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI.
Atger, V., Moya, M. D. L. L., Bamberger, M. J., Francone, O. L., Cosgrove, P. G., Tall, A. R., Walsh, A., MOATTI, N., & Rothblat, G. H. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118326 · Cited by 44
Genetic variation in cholesterol ester transfer protein, serum CETP activity, and coronary artery disease risk in Asian Indian diabetic cohort
Schierer, A., Been, L. F., Ralhan, S. K., Wander, G. S., Aston, C. E., & Sanghera, D. K. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834dc9ef · Cited by 43
Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus
Drew, B. G., Carey, A. L., Natoli, A. K., Formosa, M. F., Vizi, D., Reddy-Luthmoodoo, M., Weir, J. M., Barlow, C. K., van Hall, G., Meikle, P. J., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.p012518 · Cited by 42
Self-citation
Apo A5 −1131T/C, FgB −455G/A, −148C/T, and CETP TaqIB gene polymorphisms and coronary artery disease in the Chinese population: a meta-analysis of 15,055 subjects
Li, Y.-Y., Wu, X.-Y., Xu, J., Qian, Y., Zhou, C.-W., & Wang, B. (2013) · Molecular Biology Reports · doi:10.1007/s11033-012-2257-9 · Cited by 41
Elevated CETP Activity Improves Plasma Cholesterol Efflux Capacity From Human Macrophages in Women
Villard, E. F., Khoury, P. E., Duchêne, E., Bonnefont‐Rousselot, D., Clément, K., Bruckert, É., Bittar, R., Goff, W. L., & Guérin, M. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.252841 · Cited by 41
MicroRNA-33 in atherosclerosis etiology and pathophysiology
Chen, W., Zhang, M., Zhao, G., Fu, Y., Zhang, D., Zhu, H., & Tang, C. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.11.025 · Cited by 39
On-Statin Cholesteryl Ester Transfer Protein Mass and Risk of Recurrent Coronary Events (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)
Khera, A. V., Wolfe, M. L., Cannon, C. P., Qin, J., & Rader, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.03.057 · Cited by 38
Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition
Furbee, J. W., & Parks, J. S. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00201-0 · Cited by 35
SERUM LIPOPROTEINS AND THE EVALUATION OF ATHEROSCLEROSIS
Gofman, J. W. (1956) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1956.tb36833.x · Cited by 34

Research works printed but not linked: 3

Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380, 572–580 (2012). This is the first study to test the causality of the relationship between CHD and HDL by genome-wide Mendelian randomization analysis. · DOI · Paper page
Goffinet, M. et al. Anti-atherosclerotic effect of CER-001, an engineered HDL-mimetic, in the high-fat diet-fed LDLr knock-out mouse. Circulation Abstr. 126, A18667 (2012).
Keyserling, C. H. et al. CER-001, a synthetic HDL-mimetic, safely mobilizes cholesterol in healthy dyslipidemic volunteers. Circulation Abstr. 124, A15525 (2011).

Sorted by citations

Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679
Protein-Based Nanoparticles as Drug Delivery Systems
Hong, S., Choi, D. W., Kim, H. N., Park, C. G., Lee, W., & Park, H. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070604 · Cited by 642
Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials
Mansoor, N., Vinknes, K. J., Veierød, M. B., & Retterstøl, K. (2016) · British Journal of Nutrition · doi:10.1017/s0007114515004699 · Cited by 439
Elimination of established tumors with nanodisc-based combination chemoimmunotherapy
Kuai, R., Yuan, W., Son, S., Nam, J., Xu, Y., Fan, Y., Schwendeman, A. A., & Moon, J. J. (2018) · Science Advances · doi:10.1126/sciadv.aao1736 · Cited by 355
High-Density Lipoproteins: Nature’s Multifunctional Nanoparticles
Kuai, R., Li, D., Chen, Y. E., Moon, J. J., & Schwendeman, A. A. (2016) · ACS Nano · doi:10.1021/acsnano.5b07522 · Cited by 346

See all 355

Authors: Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E.
Affiliations: Baker Heart and Diabetes Institute (AU)
Inserm (FR)
University of Oxford (GB)
Corresponding author: Kingwell, Bronwyn A.
ORCID: Kingwell, Bronwyn A.
Chapman, M. John
Kontush, Anatol
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2014-05-23
Volume: 13
Issue: 6
Pages: 445-464
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd4279
OpenAlex: W1993577107
Cited by: 354
References: 228
Citations by year: 2026: 11 · 2025: 15 · 2024: 9 · 2023: 28 · 2022: 22 · 2021: 21 · 2020: 22 · 2019: 33 · 2018: 33 · 2017: 43 · 2016: 53 · 2015: 51 · 2014: 12
FWCI: 10.00
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: HDL cholesterol, HDL-targeted therapy, HDL particle number, reverse cholesterol transport, atheroprotection, cardiovascular disease, clinical trial failure
MeSH terms: Animals, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Humans, Phosphatidylcholine-Sterol O-Acyltransferase, Lipoproteins, HDL, Models, Biological, Niacin, Recombinant Proteins, Drugs, Investigational, Up-Regulation, Apolipoprotein A-I, Cholesterol Ester Transfer Proteins, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HDL-targeted therapies: progress, failures and future

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks